Regenstrief and Merck Estblish Evidence-based Care Collaboration
Print Friendly Template
Merck and Regenstrief Institute Establish Evidencebased Care Collaboration
WHITEHOUSE, N.J., and INDIANAPOLIS, Ind., Nov. 8, 2012 -- The Regenstrief Institute and
Merck, known as MSD outside the United States and Canada, have signed a five-year
agreement to collaborate on a range of projects that will use clinical data to inform personalized
delivery of health care. The work will explore novel methods for studying diseases and
interventions for chronic conditions such as diabetes, cardiovascular disease and osteoporosis.
Ultimately, the Regenstrief-Merck collaboration seeks to improve the health of patients
through data analytics, health care innovation, education and research that supports evidencebased health care.
Financial details were not disclosed.
"Regenstrief has a passion for determining how personalization of medicine can be
achieved by better understanding and using health data," said Regenstrief investigator and
innovations officer Jon Duke, M.D., who serves as the institute's lead investigator for the
partnership. "Regenstrief brings rigorous science to clinical environments and has more than 40
years of experience as an international leader in improving health care delivery through
informatics and health services research. With Merck's depth of expertise and its global reach,
we hope to develop and test new approaches to care, and advance successful models of health
care broadly." Dr. Duke also is an assistant professor of medicine at the Indiana University
School of Medicine.
Both Regenstrief, a medical research organization closely associated with the Indiana
University School of Medicine, and Merck, a global health care leader, are committed to
generating new knowledge to improve health.
"This type of novel academic-industry collaboration can advance our understanding of a
number of critical therapeutic areas, enabling novel use of health information technology to
enhance drug development, medication safety and the personalization of therapeutics," said
Sachin H. Jain, M.D., chief medical information and innovation officer at Merck.
An internationally respected informatics and health care research organization, the Regenstrief
Institute is recognized for its role in improving quality of care, increasing efficiency of health care
delivery, preventing medical errors and enhancing patient safety. Established in 1969, the
institute is closely associated with the Indiana University School of Medicine and the Health and
Hospital Corporation of Marion County.
Today's Merck is a global health care leader working to help the world be well. Merck is known
as MSD outside the United States and Canada. Through our prescription medicines, vaccines,
biologic therapies, and consumer care and animal health products, we work with customers and
operate in more than 140 countries to deliver innovative health solutions. We also demonstrate
our commitment to increasing access to health care through far-reaching policies, programs and
partnerships. For more information, visit www.merck.com and connect with us on Twitter,
Facebook and YouTube.
Merck Forward-Looking Statement
This news release includes "forward-looking statements" within the meaning of the safe harbor
provisions of the United States Private Securities Litigation Reform Act of 1995. Such
statements may include, but are not limited to, statements about the benefits of the merger
between Merck and Schering-Plough, including future financial and operating results, the
combined company's plans, objectives, expectations and intentions and other statements that
are not historical facts. Such statements are based upon the current beliefs and expectations of
Merck's management and are subject to significant risks and uncertainties. Actual results may
differ from those set forth in the forward-looking statements.
The following factors, among others, could cause actual results to differ from those set forth in
the forward-looking statements: the possibility that all of the expected synergies from the merger
of Merck and Schering-Plough will not be realized, or will not be realized within the expected